Cardarine.

Quick Overview.

Cardarine, also known as GW-501516 or Endurobol, is often grouped with SARMs, but it is not a SARM. It is a Peroxisome Proliferator-Activated Receptor Delta (PPARδ) agonist. Originally developed in the 1990s by Ligand Pharmaceuticals and GlaxoSmithKline to treat metabolic and cardiovascular diseases, it gained massive popularity in the fitness community for its extraordinary ability to increase cardiovascular endurance and accelerate fat loss.[1]

Cardarine fundamentally changes how the body uses energy. Instead of burning glucose (carbohydrates) for energy during exercise, it forces the body to preferentially burn fatty acids. This results in a profound increase in stamina—often referred to as "exercise in a bottle"—and rapid fat oxidation. However, its clinical development was completely abandoned in 2007 after long-term animal studies revealed a significant risk of cancer development.[2]

• Primary Use Case: Extreme cardiovascular endurance enhancement and rapid fat loss.
• Mechanism: PPARδ agonist (forces the body to burn fat for fuel instead of glucose).[3]
• Who it is for: Endurance athletes, or bodybuilders looking to maximize fat loss during a cutting phase.
• Who it is NOT for: Anyone concerned about the preclinical cancer data, or tested athletes (it is highly detectable).

The Protocol & Usage Guide.

confidence_tier: well-established

Cardarine is orally bioavailable and has a half-life of approximately 12 to 24 hours. It is typically dosed once per day, usually 1-2 hours before cardiovascular exercise to maximize its endurance-enhancing effects.[4]

Standard Dosing Schedule

Cycle Length & Discontinuation Protocol

• Cycle Length: 4 to 8 weeks. Due to the preclinical safety concerns regarding cellular proliferation, users are strongly advised not to exceed 8 weeks of continuous use.
• Discontinuation (PCT): Because Cardarine is not a SARM and does not interact with the androgen receptor, it causes zero testosterone suppression. No Post Cycle Therapy (PCT) is required if Cardarine is run by itself.

Nutritional Support & Recommended Supplements.

confidence_tier: well-established

Safety, Interactions & Side Effect Management.

confidence_tier: well-established

Side Effect Profile

Contraindications

• Absolute: Individuals with a personal or strong family history of cancer or tumor growth.
• Absolute: Tested athletes (WADA tests specifically for GW-501516).

Drug Interactions

• Insulin / Hypoglycemic Agents: Because Cardarine alters glucose metabolism and improves insulin sensitivity, diabetics taking insulin must monitor their blood sugar closely to avoid hypoglycemia.

Common Stacks & Combinations.

confidence_tier: community

Body Composition & Training Guide.

confidence_tier: community

• The "Third Lung": The most immediate and profound effect of Cardarine is the endurance boost. Users frequently report that their cardiovascular stamina doubles within the first week. Running, cycling, or swimming becomes significantly easier.
• Fat Oxidation: By shifting the body's energy preference from glucose to lipids, Cardarine directly burns stored body fat for fuel, making it highly effective for contest prep or general weight loss.
• Muscle Fiber Shift: Preclinical data suggests Cardarine actually stimulates the conversion of fast-twitch (Type II) muscle fibers into slow-twitch (Type I) endurance fibers. This is excellent for marathon runners, but potentially counterproductive for powerlifters seeking maximum explosive strength.

Storage, Handling & Accessibility.

confidence_tier: well-established

• Storage: Store liquid solutions or capsules at room temperature in a cool, dark place.
• WADA Status: Banned in competitive sports under section S4 (Hormone and Metabolic Modulators). In 2013, WADA took the unprecedented step of issuing a public health warning about the dangers of GW-501516 due to its toxicity.
• Cost & Accessibility: Widely available from research chemical vendors. Typically costs $40-$60 for a 30mL bottle (usually dosed at 20mg/mL).

Bloodwork Monitoring Guide.

confidence_tier: well-established

Comparison to Similar Compounds.

confidence_tier: well-established

Deep Dive (For Advanced Researchers).

confidence_tier: well-established

Mechanism of Action

GW-501516 is a highly selective agonist of the Peroxisome Proliferator-Activated Receptor Delta (PPARδ). PPARδ is a nuclear hormone receptor that regulates the expression of genes involved in lipid and glucose metabolism. Upon activation, GW-501516 promotes the expression of genes that increase fatty acid oxidation and energy expenditure in skeletal muscle and adipose tissue.[5]

The Cancer Controversy

The clinical development of GW-501516 was abruptly halted in 2007. GlaxoSmithKline conducted standard two-year carcinogenicity bioassays in Wistar Han rats and CD-1 mice. The results were alarming: GW-501516 caused a dose-dependent increase in the incidence of multiple tumor types across various organs, including the liver, stomach, thyroid, and testes.[6]

• The Counter-Argument: The bodybuilding community often argues that the doses used in the rat studies (up to 30 mg/kg/day) were astronomically higher than human doses (0.2 mg/kg/day). However, tumors were also observed at the lowest dose tested (3 mg/kg/day), which, when adjusted for human equivalent dosing (HED) based on body surface area, is uncomfortably close to the 20mg/day dose used by athletes.[7]
• The Mechanism of Proliferation: PPARδ activation is known to promote cell survival and inhibit apoptosis (programmed cell death). While this is beneficial for muscle endurance, it also means that if a cell becomes cancerous, PPARδ activation may prevent the body from destroying it, allowing the tumor to grow rapidly.[8]

Clinical Trial Summary

Before its abandonment, GW-501516 showed incredible promise in human trials for metabolic syndrome.

• Lipid Improvement: A Phase II trial in healthy volunteers and patients with low HDL cholesterol showed that 10mg of GW-501516 daily increased HDL by up to 16.9% and decreased fasting triglycerides by up to 30%.[9]
• Metabolic Syndrome: Another study in obese men demonstrated that GW-501516 reversed multiple abnormalities associated with metabolic syndrome, significantly improving insulin sensitivity and reducing liver fat without causing weight loss on its own (without exercise).[10]

Frequently Asked Questions (FAQ).

confidence_tier: community

Q: Will Cardarine give me cancer? A: The honest answer is that no one knows for sure in humans. It definitively caused cancer in rodents at multiple doses. While human metabolism differs from rodents, the mechanism of action (inhibiting apoptosis) provides a plausible pathway for tumor promotion. Use at your own extreme risk.

Q: Do I need a PCT? A: No. Cardarine does not affect the endocrine system or testosterone production.

Q: Why is WADA so concerned about it? A: WADA rarely issues public health warnings for banned substances. They did so for GW-501516 in 2013 because athletes were buying it on the black market, and WADA wanted to explicitly warn them about the severe preclinical toxicity findings.

International Regulatory Status.

confidence_tier: well-established

Decision Tree.

confidence_tier: community

[Goal: Extreme Endurance and Fat Loss?]
  |
  +-- Are you comfortable with the preclinical cancer data?
        |
        +-- (No) -> Do not use Cardarine. Consider L-Carnitine or standard cardio.
        |
        +-- (Yes) -> Cardarine is the most potent endurance enhancer available.
              |
              +-- Take 10-20mg daily, 1-2 hours before cardio.
              +-- Do not exceed 8 weeks of continuous use.
              +-- No PCT required.

Schema.org Data.

{
  "@context": "https://schema.org",
  "@type": "MedicalEntity",
  "name": "Cardarine",
  "alternateName": ["GW-501516", "Endurobol", "GSK-516"],
  "description": "A PPARδ agonist originally developed for metabolic diseases, widely used off-label for extreme endurance enhancement and fat loss. Clinical development was abandoned due to cancer risks in animal models.",
  "legalStatus": {
    "@type": "DrugLegalStatus",
    "description": "Abandoned investigational drug. Not FDA approved. Banned by WADA."
  }
}

What we cited.